Colorectal cancer (CRC) continues to be a significant health challenge, necessitating the development of efficient therapeutic strategies. Drug repurposing, which involves the use of existing medications for new purposes, presents a promising opportunity. Metformin, a widely used antidiabetic drug, has demonstrated potential anticancer effects. To enhance its efficacy, we formulated nano‐metformin, metformin encapsulated within pectin nanoparticles. Our study aimed to evaluate the superiority of nano‐metformin over free metformin in treating CRC. The cytotoxicity of both metformin and nano‐metformin on Caco‐2 CRC cells was assessed using the MTT assay, revealing a significant dose‐dependent inhibition of cell growth using nano‐metformin. The anti‐inflammatory potential was evaluated by measuring the levels of nitric oxide and the pro‐inflammatory cytokines IL‐2 and IL‐6 following lipopolysaccharide (LPS) induction, and the results revealed that treating LPS‐induced cells with nano‐metformin significantly reduced the production of these inflammatory mediators. To elucidate the mechanism of cell death, we employed an acridine orange/ethidium bromide staining assay, which revealed the enhancement of apoptotic cell death following treatment with nano‐metformin. Additionally, we examined the expression of key apoptotic regulators using real‐time qPCR. Nano‐metformin, in particular, significantly downregulated the expression of the antiapoptotic markers Bcl‐2 and Survivin while upregulating the proapoptotic caspases 3, 7, and 9. The comet assay revealed significant DNA damage induced by treatment with the nano‐metformin compared with that in the free form. Moreover, nano‐metformin significantly reduced the migration ability of cells. In conclusion, our work revealed the superior efficacy of our formulated nanoform over free metformin, highlighting its potential as a promising therapeutic agent for CRC treatment.